Argo Biopharma to present at 44th J.P. Morgan Healthcare Conference on Jan. 11, 2026 in Shanghai and Boston. Dr. Shu to speak.
On January 11, 2026, Argo Biopharmaceutical Co., Ltd. revealed from Shanghai and Boston its plans for advancing siRNA therapies, with Dr. Dongxu Shu, a Co-Founder, Chairman of the Board, and CEO, leading the efforts. Argo Biopharma is a clinical-stage biotechnology company dedicated to developing innovative siRNA treatments for various conditions.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments